|
Session 87
Poster Abstracts
Antiretroviral Therapy: Randomized Trials, Strategies and Long-Term Outcomes
Tuesday, 1:30 - 3:30 pm
Poster Hall |
| 519 |
Randomized Intensification of a Triple Nucleoside Regimen with Efavirenz or Tenofovir in ACTG 5095
Roy Gulick*1, C Lalama2, C Shikuma3, H Ribaudo2, B Schackman1, W Meyer4, K Squires5, E Acosta6, K Klingman7, D Kuritzkes8, and the ACTG 5095 Study Team
1Weill-Cornell Med Coll, New York, NY, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Hawaii, Honolulu, US; 4Quest Diagnostics, Baltimore, MD, US; 5David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US; 6Univ of Alabama at Birmingham, US; 7Division of AIDS, NIAID, NIH, Bethesda, MD, US; and 8Brigham and Women's Hosp, Boston, MA, US |
| 520 |
Tipranavir Achieves Twice the Rate of Treatment Response and Prolongs Durability of Response vs Comparator PI in ART-experienced Patients, Independent of Baseline CD4 Cell Count or Viral Load: Week 48 RESIST 1 and 2 Combined Analyses
Christine Katlama*1, S Walmsley2, C Hicks3, P Cahn4, D Neubacher5, J Villacian5, and for the RESIST Investigators
1Hosp Pitié-Salpétrière, Paris, France; 2Toronto Gen Hosp, Univ of Toronto, Canada; 3Duke Univ Sch of Med, Durham, NC, US; 4Fndn Huésped, Buenos Aires, Argentina; and 5Boehringer Ingelheim Pharma, Ridgefield, CT, US |
| 521 |
3-year Final Results of a Simplification Trial with Nevirapine, Efavirenz, or Abacavir as Substitutes of Protease Inhibitors in Patients with HIV Infection (The NEFA Study)
Esteban Martínez*, J Arnaiz, E De Lazzari, A Cruceta, J Gatell, and NEFA Study Team
Hosp Clin, Barcelona, Spain |
522
 |
A Randomized Pilot Study of Delayed ART Switch in Subjects with Detectable Viremia on HAART
Sharon Riddler*1, H Jiang2, S Deeks3, A Tenorio4, H Huang2, D Kuritzkes5, E Acosta6, A Landay4, J Bartlett7, and AIDS Clin Trials Group
1Univ of Pittsburgh, PA, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of California, San Francisco, US; 4Rush Univ Med Ctr, Chicago, IL, US; 5Brigham and Women's Hosp, Boston, MA, US; 6Univ of Alabama at Birmingham, US; and 7Duke Univ Med Ctr, Durham, NC, US |
523
|
Early vs Deferred HAART Switch in Heavily Pre-treated HIV Patients with Low Viral Load Level and Stable CD4 Cell Count
Paola Nasta*1, A Matti1, G Cocca2, G Zoboli3, M Nigro4, M Colombo5, C Calzetti6, F Barchiesi7, F Gatti1, G Carosi1, and IM.P.R.O.V.E Master Study Group
1Inst Infectious and Tropical Diseases, Brescia, Italy; 2Hosp di Circolo, Busto Arsizio, Italy; 3Hosp Reggio Emilia, Italy; 4Hosp Lecco, Italy; 5Hosp Como, Italy; 6Hosp Parma, Italy; and 7Univ Ancona, Italy |
524
|
Defining the Immunologic Consequences of Early vs Delayed Treatment Modifications Using Marginal Structural Models
Maya Petersen*1, M van Der Laan1, J Martin2, and S Deeks2
1Univ of California, Berkeley, US and 2Univ of California, San Francisco, US |
| 525 |
Estimating the Optimum CD4 Threshold for Starting HAART in ART-naïve HIV-infected Individuals
Jonathan Sterne*1, M May1, D Costagliola2, M Egger3, R Hogg4, A D'Arminio Monforte5, G Chene6, M Gill7, F De Wolf8, S Cole9, and ART Cohort Collaboration
1Univ of Bristol, UK; 2INSERM U720, Hosp Pitie-Salpetriere, Paris, France; 3Inst of Social and Preventive Med, Univ of Berne, Switzerland; 4Univ of British Columbia, Vancouver, Canada; 5Inst of Infectious and Tropical Diseases, Univ of Milan, Italy; 6Inst de Sante Publ, Univ Victor Segalen, Bordeaux, France; 7Southern Alberta HIV Clin, Calgary, Canada; 8HIV Monitoring Fndn, Academic Med Ctr, Univ of Amsterdam, The Netherlands; and 9Johns Hopkins Univ, Bloomberg Sch of Publ Hlth, Baltimore, MD, US |
526
|
Predictors of Clinical Response to Salvage Therapy in a Late Salvage Population with Multidrug-resistant HIV in the OPTIMA Trial
Joel Singer*1, D Ayers1, D Cameron2, M Holodniy3, S Brown4, T Kyriakides5, A Babiker6, A Anis1, M Youle6, and M Schechter1
1Canadian HIV Trials Network, Vancouver, Canada; 2Ottawa Hosp, Canada; 3VA Palo Alto Hlthcare System, CA, US; 4VAMC, Bronx , NY, US; 5VA Cooperative Studies Prgm Coordinating Ctr, West Haven, CT, US; and 6Med Res Council Clin Trials Unit, London, UK |
| 527 |
Discordant Responses to HAART and Clinical Outcomes among Injection Drug Users in Baltimore, Maryland
Shruti H Mehta*1, G Lucas1, J Astemborski1, G Kirk1, D Vlahov2, and N Galai1
1Johns Hopkins Univ, Baltimore, MD, US and 2New York Academy of Med, NY, US |
| 528 |
T Cell Activation Is Inversely Associated with CD4+ T Cell Increase after HAART, and Predicts CD4 Gains at 48 Weeks after Controlling for Baseline CD4 Count and Plasma HIV RNA Level
Benigno Rodriguez*1, J Spritzler2, E Chan2, R Gandhi3, P Skolnik4, D Defreitas5, D Asmuth5, G Robbins3, R Pollard5, and the ACTG 384 Study Team
1Case Western Reserve Univ, Ctr for AIDS Res, Cleveland, OH, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Massachusetts Gen Hosp, Boston, US; 4Boston Univ Med Ctr, MA, US; and 5Univ of California, Davis Med Ctr, Sacramento, US |
529
|
Increases in CD4 Cell Count to 5 Years in Persons with Sustained Virologic Suppression
Jeanne Keruly* and R Moore
Johns Hopkins Univ, Baltimore, MD, US |
| 530 |
Predictors for Changes in CD4 Cell Count 7 Years after Starting HAART
Luuk Gras*1, A Van Sighem1, C Fraser2, J Griffin2, J Lange3, F Miedema4, F De Wolf1,2, and ATHENA Cohort Study Group
1HIV Monitoring Fndn, Amsterdam, The Netherlands; 2Imperial Coll, London, UK; 3Academic Med Ctr, Amsterdam, The Netherlands; and 4Univ Med Ctr, Utrecht, The Netherlands |
|
